Single Dose Anti-IL-23 Antibody SCH 900222 versus Placebo in Subjects with Crohn's Disease.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2010
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 12 Mar 2010 New trial record